Webinar July 2026 – Prof. Dailey

On Wednesday, July 29, 2026, an online seminar on "Accommodation wanted: Finding a good home for poorly soluble drugs to treat lung infections" will be held at 3.30 p.m. (CEST).

The speaker will Prof. Dr. Lea Ann Dailey from University of Vienna, Austria.

Here you can register for the webinar.

Abstract

Treating lung infections with inhaled anti-infectives can have many advantages but is also beset with challenges. In particular, the delivery of poorly soluble anti-infectives in sufficiently high doses has been identified as an unmet therapeutic need. The reason is that conventional dry powder formulations are particularly challenging for poorly soluble anti-infectives because the high dose combined with the slow dissolution kinetics can induce particle accumulation in the lungs accompanied by non-specific adverse effects, such as generalized inflammation with an influx of immune cells and development of foamy macrophages.

Liposomal formulations of poorly soluble compounds have the potential to incorporate solubilized drug at the high, therapeutically relevant concentrations for treating lung infections, can positively influence drug pharmacokinetics and show potential to enhance the therapeutic efficacy of anti-infectives, while reducing resistance development and systemic side effects.

Using bedaquiline, a synthetic small molecule, and two different classes of (moderately) poorly soluble natural product-derived anti-infectives, we will discuss how well-designed liposomal systems for poorly soluble compounds could be developed into interesting platform technologies for inhaled anti-infectives.